started · updated
Anvisa warns of illegal tirzepatide powder sales on social media
Brazil's National Health Surveillance Agency (Anvisa) has issued an urgent alert regarding the illegal sale of tirzepatide powder on social media. The agency warns that online tutorials teaching users to dilute and self-inject this powder pose severe health risks, including serious infections and sepsis, due to the lack of sterile environments and unverified product composition. Anvisa noted that it is impossible to confirm the presence of the active ingredient, its concentration, or the absence of contaminants in these unregulated products.
Separately, the Brazilian Ministry of Health is planning to incorporate weight-loss medications, such as semaglutide, into the Unified Health System (SUS). Minister Alexandre Padilha stated that the distribution will be based on strict clinical protocols for patients with obesity-related complications, rather than for aesthetic purposes. The implementation of this program is expected to take several months as it undergoes regulatory, cost, and safety evaluations by Conitec.
In the pharmaceutical market, Anvisa recently approved five new semaglutide-based medications to increase competition. Meanwhile, new generations of GLP-1 receptor agonists, including CagriSema and retatrutide, are currently in advanced clinical testing phases.
Entities
Alexander Padilha · Alexandre Padilha · Anvisa · Brazil · Conitec · Eli Lilly · Grupo Hospitalar Conceição · Ministry of Health · Mounjaro · Novo Nordisk · SUS · Unified Health System
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 16 SOURCES] The concentration, presence of impurities, and the actual presence of the active ingredient in the powder cannot be verified. www.acessa.com · www.atibaia.com.br · www.jcatibaia.com.br · maisminas.com.br · gpcnoticias.com.br · +11 more
- [○ 1 SOURCE] The distribution of weight loss drugs via SUS will be based on clinical protocols and not for aesthetic purposes. www.brasil247.com
- [● 16 SOURCES] Home preparation and injection of non-sterile powders pose risks of serious infections, including sepsis. www.acessa.com · www.atibaia.com.br · www.jcatibaia.com.br · maisminas.com.br · gpcnoticias.com.br · +11 more
- [● 9 SOURCES] Anvisa has issued an alert regarding the irregular sale of tirzepatide powder on social media. www.acessa.com · www.atibaia.com.br · www.jcatibaia.com.br · maisminas.com.br · gpcnoticias.com.br · +4 more
- [○ 1 SOURCE] The Brazilian Ministry of Health is planning to provide weight loss medications through the SUS for specific medical needs. www.brasil247.com
- [○ 1 SOURCE] New weight-loss drugs like CagriSema and retatrutide are in advanced clinical testing phases. www.tnh1.com.br
- [● 9 SOURCES] Home preparation of tirzepatide powder poses risks of serious infection, including sepsis. www.acessa.com · www.atibaia.com.br · www.jcatibaia.com.br · maisminas.com.br · gpcnoticias.com.br · +4 more
- [● 16 SOURCES] Anvisa issued an alert regarding the irregular sale of tirzepatide powder on social media. www.acessa.com · www.atibaia.com.br · www.jcatibaia.com.br · maisminas.com.br · gpcnoticias.com.br · +11 more
- [○ 1 SOURCE] The integration of weight-loss drugs into the SUS will take months due to regulatory and cost evaluation steps. www.osul.com.br
- [○ 1 SOURCE] The Brazilian Ministry of Health is preparing to offer weight-loss medications through the SUS. www.brasil247.com
- [● 2 SOURCES] Anvisa approved five new semaglutide-based medications in July to increase market competition. pontanegranews.com.br · www.osul.com.br